Search
boceprevir (Victrelis)
Indications:
- chronic hepatitis C genotype 1 in combination with peginterferon & ribavirin
Dosage:
- PO TID with food
Adverse effects:
- nausea
- headache
- anemia
- dysgeusia
Drug interactions:
- coadministration of boceprevir with ritonavir-boosted HIV protease inhibitors may reduce effectiveness, permitting HIV & HCV to proliferate; includes
- atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir [6]
Mechanism of action:
- protease inhibitor
- efficacy against HCV type-1
Interactions
drug interactions
General
antiviral protease inhibitor
Database Correlations
PUBCHEM cid=10324367
References
- Poordad F et al.
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med 2011 Mar 31; 364:1195
PMID: 21449783
- Bacon BR et al.
Boceprevir for previously treated chronic HCV genotype 1
infection.
N Engl J Med 2011 Mar 31; 364:1207
PMID: 21449784
- Jensen DM.
A new era of hepatitis C therapy begins.
N Engl J Med 2011 Mar 31; 364:1272
PMID: 21449791
- FDA NEWS RELEASE: May 13, 2011
FDA approves Victrelis for Hepatitis C
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm
- Prescriber's Letter 18(8): 2011
Victrelis (Boceprevir) and Incivek (Telaprevir) for Hepatitis C
Detail-Document#: 270802
(subscription needed) http://www.prescribersletter.com
- FDA MedWatch April 26, 2012
Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency
Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication -
Drug Interactions
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm291144.htm